Does Therapeutic Dose of Sildenafil Citrate Treatment Lead to Central Serous Chorioretinopathy in Patients With Erectile Dysfunction?

• Published in: American journal of men's health Vol. 7; no. 5; pp. 439 - 443
• Main Authors: Damar, Elif, Toklu, Yasin, Tuncel, Altug, Balci, Melih, Aslan, Yilmaz, Simsek, Saban, Atan, Ali
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.09.2013; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Adult; Aged; Central Serous Chorioretinopathy - chemically induced; Erectile dysfunction; Erectile Dysfunction - drug therapy; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors - adverse effects; Phosphodiesterase Inhibitors - therapeutic use; Piperazines - adverse effects; Piperazines - therapeutic use; Purines - adverse effects; Purines - therapeutic use; Sildenafil Citrate; Sulfones - adverse effects; Sulfones - therapeutic use; Vasodilator Agents - adverse effects; Vasodilator Agents - therapeutic use; sexual health; erectile dysfunction
• ISSN: 1557-9883; 1557-9891
• DOI: 10.1177/1557988313480808

The possible effects of sildenafil citrate administration at therapeutic dosage on visual acuity, color vision, intraocular pressure, macular thickness, macular volume, and central serous chorioretinopathy in patients with erectile dysfunction were evaluated. The study consisted of 43 male patients diagnosed as having erectile dysfunction according to the first five question version of International Index of Erectile Function (IIEF-5). All patients were given sildenafil citrate 50 mg po 2 to 3 times/week for a month. The patients were evaluated at the first week and at the end of the treatment. The macular thickness and volume assessments with optic coherence tomography did not differ significantly in foveal, parafoveal areas, parafoveal superior hemisphere, parafoveal inferior hemisphere, parafoveal temporal, superior, nasal, and inferior quadrants. Central serous chorioretinopathy was not found in any of the patients.